Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL3577945 |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
CCR2/C-C chemokine receptor type 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4015] [GtoPdb: 59] [UniProtKB: P41597] | ||||||||
ChEMBL | Antagonist activity against CCR2 in whole blood (unknown origin) assessed as reduction in CD11b upregulation | B | 8.33 | pIC50 | 4.7 | nM | IC50 | ACS Med Chem Lett (2015) 6: 439-444 [PMID:25893046] |
GtoPdb | - | - | 9.15 | pIC50 | 0.7 | nM | IC50 | ACS Med Chem Lett (2015) 6: 439-44 [PMID:25893046] |
ChEMBL | Inhibition of [125I]hMCP1 binding to CCR2 in human PBMC incubated for 30 mins at room temperature | B | 9.15 | pIC50 | 0.7 | nM | IC50 | ACS Med Chem Lett (2015) 6: 439-444 [PMID:25893046] |
ChEMBL | Displacement of [125I]MCP1 from CCR2 in human PBMC measured after 30 mins | B | 9.15 | pIC50 | 0.7 | nM | IC50 | ACS Med Chem Lett (2019) 10: 300-305 [PMID:30891130] |
ChEMBL | Antagonist activity against CCR2 in human PBMC assessed as inhibition of MCP1-induced chemotaxis at 37 degC | B | 9.62 | pIC50 | 0.24 | nM | IC50 | ACS Med Chem Lett (2015) 6: 439-444 [PMID:25893046] |
CCR5/C-C chemokine receptor type 5 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL274] [GtoPdb: 62] [UniProtKB: P51681] | ||||||||
ChEMBL | Antagonist activity against CCR5 in whole blood (unknown origin) assessed as reduction in CD11b upregulation | B | 8.37 | pIC50 | 4.3 | nM | IC50 | ACS Med Chem Lett (2015) 6: 439-444 [PMID:25893046] |
ChEMBL | Inhibition of [125I]MCP1-beta binding to CCR5 in human HT1080 cell membranes incubated for 4 to 6 hrs | B | 8.62 | pIC50 | 2.4 | nM | IC50 | ACS Med Chem Lett (2015) 6: 439-444 [PMID:25893046] |
ChEMBL | Antagonist activity at CCR5 (unknown origin) expressed in human HT1080 cells assessed as blockade of MIP1beta-binding to receptor | B | 8.62 | pIC50 | 2.4 | nM | IC50 | ACS Med Chem Lett (2019) 10: 300-305 [PMID:30891130] |
GtoPdb | - | - | 8.62 | pIC50 | 2.4 | nM | IC50 | ACS Med Chem Lett (2015) 6: 439-44 [PMID:25893046] |
Kv11.1/HERG in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL240] [GtoPdb: 572] [UniProtKB: Q12809] | ||||||||
ChEMBL | Inhibition of human ERG expressed in HEK293 cells assessed as reduction in peak tail current at holding potential of 80 mV to +20 mV by whole cell patch clamp assay | B | 5.74 | pIC50 | 1800 | nM | IC50 | ACS Med Chem Lett (2015) 6: 439-444 [PMID:25893046] |
M1 receptor/Muscarinic acetylcholine receptor M1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL216] [GtoPdb: 13] [UniProtKB: P11229] | ||||||||
ChEMBL | Inhibition of muscarinic acetylcholine receptor M1 (unknown origin) | B | 6.47 | pKi | 341 | nM | Ki | ACS Med Chem Lett (2015) 6: 439-444 [PMID:25893046] |
M2 receptor/Muscarinic acetylcholine receptor M2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL211] [GtoPdb: 14] [UniProtKB: P08172] | ||||||||
ChEMBL | Inhibition of muscarinic acetylcholine receptor M2 (unknown origin) | B | 5.4 | pKi | 4010 | nM | Ki | ACS Med Chem Lett (2015) 6: 439-444 [PMID:25893046] |
M4 receptor/Muscarinic acetylcholine receptor M4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1821] [GtoPdb: 16] [UniProtKB: P08173] | ||||||||
ChEMBL | Inhibition of muscarinic acetylcholine receptor M4 (unknown origin) | B | 6.06 | pKi | 865 | nM | Ki | ACS Med Chem Lett (2015) 6: 439-444 [PMID:25893046] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]